Rationale: Relaxin is a hormone that has been considered as a potential therapy for patients with fibrotic diseases.
Idiopathic pulmonary fibrosis (IPF) is a progressive and devastating disorder characterized by the unremitting accumulation of activated fibroblasts in the lung, which leads ultimately to respiratory failure. With a median survival of approximately 3-4 years from the time of diagnosis (1, 2) , IPF is a leading indication for lung transplant (3) . One potential therapeutic strategy to use in treating IPF is to interfere with the pathways associated with fibroblast activation and synthesis of extracellular matrix.
The observation that the hormone relaxin could loosen collagen fibers served as a strong rationale for promoting relaxin as a potential therapy for pulmonary fibrosis (4, 5) . Further evidence in support of this hypothesis came from the study of relaxin-knockout mice, in which there is progressive, age-related multiorgan fibrosis (5-7). Treatment of aged relaxin-null mice with recombinant relaxin reversed pulmonary fibrosis (6) . These data suggest that treatment of patients with IPF with relaxin or relaxin agonists might be efficacious. Enthusiasm for this strategy ebbed following the failure of a clinical trial of relaxin therapy for systemic sclerosis (SSc) (8, 9) . The recent success of relaxin in clinical trials for acute heart failure (10), however, has renewed interest in studying relaxin-based therapies in fibrotic diseases, including IPF (11, 12) .
Circulating relaxin is encoded by the relaxin 2 (RLN2) gene (5) . RLN1 has no known human function, and RLN3 is expressed in the brain (11) . The relaxins signal through the G protein-coupled receptors encoded by the four receptor genes (RXFP1-RXFP4) (13) . Relaxin/insulin-like family peptide receptor 1 (RXFP1), whose natural ligand is RLN2, is the only relaxin receptor known to be expressed in the lung (11) . Binding of relaxin to RXFP1 recruits G proteins with subsequent activation of adenylyl cyclase and elevation of cAMP (11) . Of relevance to fibrosis, induction of nitric oxide synthase 2 downstream of relaxin has been shown to increase nitric oxide/cyclic guanosine monophosphate/protein kinase Gdependent inactivation of the Rho/Rhoassociated coiled-coil-containing protein kinase, leading to cellular relaxation (14) . Nitric oxide has also been shown to inhibit profibrotic transforming growth factor (TGF)-b signaling by blocking phosphorylation of Smad2 (15) . One potential biological explanation for the failure of relaxin in SSc is that there is decreased expression of the relaxin receptor, RXFP1, in fibrosis, and this decrease in RXFP1 gene expression may prevent the protective antifibrotic activities of relaxin signaling. While we cannot answer this question definitively in SSc, data obtained from the Lung Tissue Research Consortium (LTRC; https://www.ltrcpublic.com/), which contains gene expression, demographic, and clinical data in IPF and in donor controls, may help us to predict the potential sensitivity of patients with IPF to relaxin-based therapies. To date, there have been no clinical trials that have tested relaxin in IPF. To investigate the potential application of relaxin-based therapies in IPF, we queried the LTRC gene expression dataset to determine expression of RXFP1 in IPF. We employed a relaxin-like peptide, CGEN25009 (12) , as a model of a relaxinbased therapy to test in bleomycin injury and in ex vivo human lung fibroblasts.
Methods Ethics Statement
The institutional review board and the institutional animal care and use committee of the University of Pittsburgh approved this work.
Reagents
A full list of reagents used in the experiments is available in the online supplement.
Microarray Analysis
A full description of the RNA isolation and microarray procedures is published elsewhere (16, 17) . We used publicly available data from the Lung Genomics Research Consortium (http://www.lunggenomics.org/). One hundred thirty-four patients with IPF, 48 subjects with non-IPF interstitial lung disease (non-IPF ILD), and 108 donor control subjects were selected. These data and methods are available in the Gene Expression Omnibus database (accession number GSE47460) (18) . The false discovery rate (FDR) was calculated according to the method of Benjamini and Hochberg (19) . Data were normalized using a cyclic LOESS algorithm from the Bioconductor suite of R (20) . Analyses were performed using BRB-ArrayTools Donor human fibroblasts were isolated from lungs that appeared to have no injury by histology but were deemed unacceptable for lung transplant. IPF lung fibroblasts were obtained from patients either at explant or at autopsy (21) . All fibroblasts were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and were used between passages 3 and 6.
Bleomycin-induced Lung Injury and CGEN25009 Treatment, Sircol Collagen Assay, Histology, and Flow Cytometry
Full details of the experimental protocols are available in the online supplement.
Gene Silencing or Overexpression of RXFP1
Short interfering RNA (siRNA) oligonucleotides targeting the relaxin receptor RXFP1 (SMARTpool) or nontargeting controls were purchased from GE Dharmacon (Lafayette, CO). Plasmids encoding RXFP1 or green fluorescent protein (control) were obtained from OriGene (Rockville, MD). Lentiviral constructs were generated as per the manufacturer's recommendations. Full details of the cell culture conditions are available in the online supplement.
Immunoblotting
Immunoblotting was performed as previously described (22) . Full details are available in the online supplement.
Statistical Analysis
We used the Mann-Whitney U test, analysis of variance followed by Fisher 
Results

RXFP1 Expression in IPF, SSc, and Bleomycin Injury
There has been significant interest in promoting relaxin-based therapies in fibrotic diseases (5, 6, 9, 14, 23) . To understand the role of endogenous relaxin family signaling in ILD (24), we reanalyzed publicly available microarray data from IPF and controls as described in the METHODS section. Table 1 describes the LTRC cohort. We determined the relative gene expression for RLN2 and RXFP1 ( Figure 1A) . By microarray analysis of 134 patients with IPF compared with 108 donor control subjects, we found a very small but significant increase in RLN2 gene expression (FDR , 0.05). We found that RXFP1 was decreased 2.9-fold in IPF and represented one of the most significantly downregulated genes in IPF compared with controls. To confirm that RXFP1 expression is indeed decreased at the protein level, we employed lysates from lung homogenates derived from patients with IPF and from donor control subjects and performed immunoblotting for RXFP1 ( Figures 1B  and 1C ). By immunoblotting, we detected 4.6-fold less RXFP1 in IPF compared with donor controls (P , 0.003; n = 4). We also examined lung homogenates from patients with SSc by immunoblotting ( Figures 1D  and 1E ). We found 2.8-fold less RXFP1 expression in lung homogenates from patients with SSc compared with donor controls (P = 0.05; n = 3).
Next, we determined if RXFP1 protein levels were lower in the lungs of bleomycininjured mice compared with those of uninjured controls ( Figures 1F and 1G ). Bleomycin-injured mice were killed at Day 14 after injury, and their lungs were prepared for immunoblotting. Following bleomycin injury, there was a small but significant decrease in RXFP1 expression (P = 0.078 by t test; n = 6 per group). We next tested the efficacy of a relaxin-like peptide agonist, CGEN25009, which was effective at preventing bleomycin-induced pulmonary fibrosis (20) . In this experiment, we determined if treatment of bleomycin-injured mice with CGEN25009 beginning at either Day 7 or Day 12 after injury would decrease pulmonary fibrosis. We induced pulmonary fibrosis with bleomycin as described in the METHODS section. Subcutaneous pumps that dosed CGEN25009 or vehicle were implanted ( Figures 1H and 1I ).
Ashcroft staining was performed by two blinded reviewers (see Figure E1 in the online supplement). The interrater correlation coefficient was 81%. Following injury with CGEN25009 or vehicle treatment beginning at either Day 7 or Figure E3 ). Following bleomycin-induced injury and CGEN25009 treatment, beginning at Day 12, decreases in fibronectin and a-smooth muscle actin (a-SMA) mRNA were observed in flowsorted tdTomato 1 cells compared with vehicle controls (Figures 1I-1K ).
Immunoblotting of whole-lung homogenates showed significantly less a-SMA in CGEN25009-treated mice ( Figures 1L and 1M) . Analysis of the bronchoalveolar lavage showed significant reductions in neutrophils, macrophages, T cells, and B cells in CGEN25009-treated mice compared with vehicle controls ( Figure 1N ). Thus, CGEN25009 decreased several measures of bleomycin-induced lung injury in mice: acid-soluble collagen content; expression of the myofibroblast differentiation marker a-SMA; and inflammation as measured by the decreased accumulation of neutrophils, macrophages, and lymphocytes.
RXFP1 Expression Is Associated with Distinct Patterns of Gene Expression in IPF
We found that RXFP1 expression is decreased in IPF. To determine the potential clinical implications of RXFP1 gene expression in IPF, we returned to the LTRC data. Considering only the patients with IPF, we determined the effect of RXFP1 expression on pulmonary function (Figures 2A-2E ) and on whole-lung gene expression ( Figure 2F) .
We arranged the patients with IPF into four equal quartiles based on RXFP1 expression. As shown in Figure 2A , RXFP1 expression increased from quartiles 1-4 (P , 0.0001 for trend by one-way analysis of variance; n = 33-34/quartile). There was no relationship between sex ( Figure 2B ) (P = not significant by x 2 for trend), age ( Figure 2C) , and RXFP1 quartile. To determine if RXFP1 gene expression was associated with pulmonary function, we performed univariate regression analysis ( Figures 2D and 2E and Table 2) . By univariate analysis, we found that RXFP1 gene expression predicted FVC in IPF and in a cohort of IPF and non-IPF ILD. We also found that RXFP1 gene expression predicted DL CO for IPF and non-IPF ILD. Next, to adjust for the confounding effects of clinical and demographic variables, we performed multivariate regression analyses (Table 3) , employing the gene expression data combined with demographics and cross-sectional measures of exercise tolerance and quality of life derived from the LTRC data. In our multivariate model, we found that RXFP1 gene expression was directly associated with FVC and DL CO .
Having shown clinically relevant differences in patients with IPF based on gene expression for RXFP1, we hypothesized that patients with IPF would be "transcriptomically" distinct based on RXFP1 gene expression. To test this hypothesis, we generated a heatmap of the patients with IPF and arranged the patients in columns based on increasing RXFP1 expression ( Figure 2F ). Each of the quartiles is marked by a break. Patients in quartiles 1 and 2 were defined as "RXFP1-low," and patients in quartiles 3 and 4 were defined as "RXFP1-high." With this analysis, we found that 5,371 genes (FDR , 0.05) were differentially expressed between the RXFP1-high and RXFP1-low patients. The 20 most upregulated and most downregulated genes are presented in Tables E1 and E2 , respectively. We subjected the differentially expressed gene list to Ingenuity Pathway Analysis (QIAGEN, Redwood City, CA). Table E3 shows
TGF-b Regulates RXFP1 in Donor and IPF Lung Fibroblasts
We have shown above that RXFP1 expression is decreased in IPF and that lower expression of RXFP1 may have clinically relevant implications. In the next set of experiments, we determined if the loss of RXFP1 was mechanistically related to a common pathologic feature of fibrosis-differentiation of fibroblasts to myofibroblasts. TGF-b signaling is central to this pathway (25) . To test this hypothesis, donor or IPF human lung fibroblasts (26) were stimulated in vitro with TGF-b (Figures 3A-3C ). After stimulation with TGF-b or vehicle control, cell lysates were subjected to immunoblotting for RXFP1. At baseline, RXFP1 protein expression was significantly higher in donor fibroblasts than in IPF fibroblasts ( Figures 3A and 3B ). Following stimulation with TGF-b, RXFP1 expression decreased significantly in both donor and IPF-derived fibroblasts. It is notable that expression of RXFP1 decreased to undetectable levels in IPF fibroblasts following stimulation with TGF-b. Because we found differences in RXFP1 in IPF by microarray analysis, we hypothesized that we would detect decreased RXFP1 mRNA in lung fibroblasts following TGF-b stimulation ( Figure 3C ). Indeed, we found, in parallel to our findings at the protein level, that mRNA for RXFP1 decreased after TGF-b stimulation and was lower in unstimulated IPF lung fibroblasts than in donor controls. We performed a dose-response analysis with TGF-b and found that the maximum suppression of RXFP1 expression was observed at a dose of 10 ng/ml ( Figures 3D and 3E) .
TGF-b signals through either Smad or non-Smad pathways. Next, we therefore determined if the Smad signaling inhibitor (TGF-b receptor I/activin-like kinase receptor 5 inhibitor) SB431542 (27) would block the TGF-b-mediated loss of RXFP1 in donor fibroblasts. To test this hypothesis, donor lung fibroblasts were incubated in the presence of SB431542 and then stimulated with TGF-b for 24 hours (Figures 3F and 3G ). Without SB431542, stimulation with TGF-b decreased expression of RXFP1. There was no effect of SB431542 on RXFP1 expression without TGF-b. SB431542 completely blocked the effect of TGF-b on RXFP1 expression. This suggests that the loss of RXFP1 in response to TGF-b is dependent on classical Smad signaling.
We next determined the effect of CGEN25009 on expression of RXFP1, collagen I, and a-SMA (Figures 3H-3K ). Donor fibroblasts were incubated with CGEN25009, followed by stimulation with TGF-b. We found that CGEN25009 was able to prevent the loss of RXFP1 associated with TGF-b treatment. In addition, CGEN25009 prevented the augmented expression of collagen I and a-SMA associated with TGF-b. This observation supports previous studies of recombinant relaxin on myofibroblast differentiation (28, 29) . 
Relaxin-like Effects of CGEN25009 Are Dependent upon RXFP1 Expression
If there is a lack of RXFP1 expression, is relaxin family signaling decreased in IPF lungs? If relaxin family signaling is indeed impaired in IPF, it would suggest that only a subset of patients with relatively higher expression of RXFP1 would be predicted to respond to relaxin-based therapies. To test this hypothesis, we stimulated donor fibroblasts with the relaxin-like peptide CGEN25009 in the presence or absence of RXFP1 gene silencing by siRNA and determined the effect on multiple markers of myofibroblast function. Cells were incubated with nontargeting siRNA (siControl) or RXFP1-targeting siRNA (siRXFP1) oligonucleotides and then stimulated with CGEN25009. Cells were then lysed and processed for immunoblotting for phosphorylated and total myosin light chain 20 (MLC20), a marker of myofibroblast contractility (14) , collagen I, and the myofibroblast marker a-SMA. In the presence of siRXFP1, RXFP1 protein expression as determined by our immunoblotting conditions was undetectable ( Figures 4A and 4B ). In the presence of normal RXFP1 expression, stimulation of donor lung fibroblasts led to decreased phosphorylation of MLC20 ( Figures 4A and 4C) . However, following silencing of RXFP1, phosphorylation of MLC20 actually increased, and the effect of CGEN25009 on phosphorylation of MLC20 was no longer present. Similarly, stimulation of siControl cells with CGEN25009 decreased collagen I expression ( Figures 4A and 4D ). With loss of RXFP1 expression, collagen I expression was increased, and the decrease of collagen I observed with CGEN25009 was no longer present. CGEN25009 completely blocked expression of a-SMA in siControl cells, but this effect was lost following silencing of RXFP1 (Figures 4A and 4E) .
These results collectively support the hypotheses that myofibroblast function is critically linked to RXFP1 expression and that the relaxin-like effects of CGEN25009 are dependent on RXFP1 expression. These results further support an earlier report that the antimyofibroblast effects of relaxin depend on expression of RXFP1 (29) . Hypothesizing that donor and IPF fibroblasts express different levels of RXFP1 at baseline, we next determined if these cells exhibited different sensitivity to CGEN25009. To test this possibility, donor or IPF fibroblasts were incubated in the presence of CGEN25009 ranging from 1 to 350 nM. Immunoblotting for phosphorylated and total MLC20 was performed ( Figures 4F and 4G) . We found higher phosphorylation of MLC20 in IPF fibroblasts than in donor fibroblasts in the presence of the lowest concentration of CGEN25009. Loss of phosphorylation of MLC20 was observed at 35 nM in donor lung fibroblasts and at 350 nM in IPF lung fibroblasts. Densitometry of the Definition of abbreviations: CI = confidence interval; DL CO = diffusing capacity of the lung for carbon monoxide; RXFP1 = relaxin/insulin-like family peptide receptor 1; SGRQ = St. George's Respiratory Questionnaire. Variables with P < 0.2 in univariate analysis were entered into both models. Final models were selected by using a backward stepwise approach. *n = 114; R 2 = 0.26. † n = 103; R 2 = 0.49 (one outlier was removed).
immunoblots was plotted as a function of the logarithmic scale of the concentrations of CGEN25009. The best-fit curve estimated that the half-maximal inhibitory concentrations of CGEN25009 were 22 nM in donor fibroblasts and 320 nM in IPF fibroblasts. These data support the conclusion that IPF lung fibroblasts are less sensitive to CGEN25009 than donor lung fibroblasts. We next determined if overexpression of RXFP1 in IPF fibroblasts would restore sensitivity to CGEN25009. We infected IPF fibroblasts with empty (green fluorescent protein) or RXFP1-expressing lentiviral constructs, followed by stimulation with escalating doses of CGEN25009 ( Figures 4H and 4I) . We found that, with overexpression of RXFP1 in these experimental conditions, the halfmaximal inhibitory concentration of CGEN25009 in IPF fibroblasts was reduced from 838 nM to 18.7 nM, a 45-fold change.
Discussion
We found that RXFP1 gene expression is significantly decreased in the lungs of patients with IPF. Our findings were corroborated by studies with ex vivo lung fibroblasts from patients with IPF and donor control subjects stimulated with the central profibrotic signal TGF-b. The reduction of RXFP1 in bleomycin injury was far less vigorous. These findings have potential ramifications for translating relaxin-based therapies in IPF. First, in the cross-sectional LTRC dataset, we found that RXFP1 gene expression was a significant predictor of FVC and DL CO by univariate and multivariate analyses. Second, RXFP1-high patients and RXFP1-low patients, who all have IPF, were distinguished from each other by 5,371 genes. Third, we found that a relaxin-like peptide, CGEN25009, required RXFP1 expression to transduce downstream cell signaling in fibroblasts. IPF fibroblasts that expressed significantly less RXFP1 than donor controls were 10-fold less sensitive to CGEN25009 than donor lung fibroblasts. When we restored expression of RXFP1 by lentivirusmediated expression, we resensitized IPF fibroblasts to the actions of CGEN25009. These data collectively suggest that patients with IPF may be less sensitive to the protective effects of relaxin-based therapies. Strategies to enhance RXFP1 expression would be predicted to sensitize patients with IPF to the effects of relaxin-based therapies.
Little is known about transcriptional regulation of RXFP1 expression. We found that RXFP1 expression was reduced in IPF fibroblasts and that expression was reduced even further in the presence of TGF-b. These data support previous observations that TGF-b is associated with reduced expression of RXFP1 (30) . In our hands, supraphysiologic in vitro concentrations of TGF-b were observed to decrease RXFP1 in IPF fibroblasts. This suggests that stimuli other than TGF-b may decrease RXFP1 expression in IPF. Incubation of IPF fibroblasts with SB431542 alone did not restore expression of RXFP1 in IPF fibroblasts to that of control fibroblasts (data not shown). Because we detected low expression of RXFP1 by microarray in IPF, we hypothesize that the mechanisms driving down RXFP1 are transcriptional. Dysregulation of microRNAs or differential methylation of RXFP1 may be at play here. External signals, perhaps hormonal, may regulate expression of RXFP1 (31, 32) . RXFP1 expression in IPF in our dataset did not differ by sex, however, suggesting that the loss of RXFP1 in fibrosis is independent of sex. So, the answer to why RXFP1 is reduced in IPF remains enigmatic. We did find that incubation of donor lung fibroblasts with CGEN25009 prevented the TGF-b-mediated loss of RXFP1. Progression of IPF may be associated with temporal decreases in RXFP1 expression. This would support treatment with relaxin agonists early in the course of the disease. Further study is needed, as the potential to increase RXFP1 expression in fibrosis may sensitize patients to the therapeutic effects of relaxin.
The distinct transcriptomic profiles of the RXFP1-high patients compared with the RXFP1-low patients may identify clinically distinct subphenotypes of patients with IPF. The LTRC dataset, which is unique, is limited by a lack of longitudinal follow-up or a replication cohort. Therefore, we can only speculate as to the prognostic significance of RXFP1 expression; however, the association of RXFP1 with FVC, the best validated marker of disease progression in IPF (33) , does suggest that the high expressers of RXFP1 are indeed "better." Another limitation of this analysis is that our assessment of RXFP1 requires tissue. As the number of surgical lung biopsies for ILD (34) decreases, replication of this study may be challenging in the absence of a surrogate biomarker for RXFP1 that can be sampled from the circulation. We did observe a small but statistically significant increase in RLN2 gene expression. However, unlike for RXFP1, we found no association of RLN2 gene expression with pulmonary function. A small study published as an abstract suggested that plasma relaxin concentrations in IPF were associated with FVC (35) . Thus, the role of plasma relaxin and pulmonary function remains an open question that merits further study.
Initial enthusiasm for the antifibrotic effects of relaxin in SSc (8, 11, 36) was ultimately dampened by the failure of relaxin in SSc (9) . Our data showing that RXFP1 expression is decreased in patients with IPF suggests that only a subset of patients with the highest expression of RXFP1 would be predicted to respond to relaxin-based therapies. Treating RXFP1-low patients with escalating doses of relaxin may predispose them to adverse effects. The decrease in RXFP1 that we observed in SSc and the association of RXFP1 with pulmonary function across non-IPF ILDs and IPF support the hypothesis that this mechanism is common to fibrotic diseases and needs to be further clarified to realize the therapeutic potential of relaxin. n Author disclosures are available with the text of this article at www.atsjournals.org.
